Optaflu
Influenza (Flu) |
---|
![]() |
Types |
Vaccines |
Treatment |
Pandemics |
Outbreaks |
See also |
Optaflu is a cell culture derived influenza vaccine manufactured by Novartis.
History
On April 27, 2007 Novartis received a positive opinion supporting European Union approval of Optaflu. It is the first influenza vaccine made in a mammalian cell line, rather than chicken eggs.[1] The vaccine will be manufactured in Holly Springs, North Carolina. The United States government is providing $500 million in construction costs and guaranteed vaccine purchases.[2]
References
- ↑ "Optaflu, the Novartis cell culture-derived influenza vaccine, receives positive opinion supporting European Union regulatory approval". Novartis. Retrieved 2009-04-29.
- ↑ Pollack, Andrew (2009). "Swine Flu Vaccine May Be Months Away, Experts Say". New York Times. Retrieved 2009-04-29.
But Novartis is building a cell culture flu vaccine factory in Holly Springs, N.C., which might be ready for use in 2010 or 2011. The federal government is providing nearly $500 million in construction costs and guaranteed vaccine purchases.
This article is issued from Wikipedia - version of the 3/16/2011. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.